Months of economic and financial market upheaval have caught up with most life-sciences venture capitalists as nearly 75 percent of US bioregions have reported double-digit year-to-year declines in both the amount of money invested and in the number of deals executed, according to fourth-quarter figures released by one VC activity tracker last week.

Thirteen of 18 regions tracked by Dow Jones VentureSource recorded drops in biopharmaceutical VC activity during the final three months of 2008, while three regions showed increases and two were unchanged.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Berkeley researchers have engineered yeast to make the molecule behind the hoppy taste of beer, Quartz reports.

King's College London researchers examine the influence of school type and genetics on academic achievement.

FiveThirtyEight writes that most who take a direct-to-consumer BRCA1/2 genetic test won't learn much from it.

In Science this week: early life experience influence somatic variation in the genome, and more.